Vistin Pharma Logo

Vistin Pharma

A leading global producer of Metformin Hydrochloride for the global healthcare market.

VISTN | OL

Overview

Corporate Details

ISIN(s):
NO0010734122
LEI:
5967007LIEEXZXFQY092
Country:
Norway
Address:
Postboks 6735 Etterstad, 0609 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vistin Pharma is a specialized pharmaceutical company and a leading global producer of Metformin Hydrochloride, the standard first-line treatment for Type 2 diabetes. The company operates as a pure-play metformin supplier, producing both Active Pharmaceutical Ingredients (API) and Direct Compressible (DC) grades for the global healthcare market. As a dedicated European manufacturer, Vistin Pharma is positioned to supply a significant portion of the world's demand for this essential medicine, with a focus on high-quality and sustainable production.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 07:40
Investor Presentation
Vistin Pharma ASA: Third quarter and YTD 2025 financial results - Attachment: V…
English 1.7 MB
2025-10-31 07:40
Quarterly Report
Vistin Pharma ASA: Third quarter and YTD 2025 financial results - Attachment: V…
English 1.5 MB
2025-10-31 07:40
Earnings Release
Vistin Pharma ASA: Third quarter and YTD 2025 financial results
English 2.2 KB
2025-10-24 10:00
Report Publication Announcement
Vistin Pharma ASA: Invitation to Q3 2025 conference call
English 2.6 KB
2025-08-15 08:00
Interim Report
Vistin Pharma ASA: Second quarter and YTD 2025 financial results - Attachment: …
English 1.6 MB
2025-08-15 08:00
Investor Presentation
Vistin Pharma ASA: Second quarter and YTD 2025 financial results - Attachment: …
English 1.9 MB
2025-08-15 08:00
Earnings Release
Vistin Pharma ASA: Second quarter and YTD 2025 financial results
English 2.1 KB
2025-08-08 10:00
Regulatory News Service
Vistin Pharma ASA: Invitation to Q2 2025 conference call
English 1.6 KB
2025-06-04 08:00
Notice of Dividend Amount
Ex dividend NOK 1.25 today
English 330 bytes
2025-05-23 09:22
Report Publication Announcement
Financial calendar
English 464 bytes
2025-05-23 09:22
Report Publication Announcement
Finansiell kalender
Norwegian 448 bytes
2025-05-22 12:59
Post-Annual General Meeting Information
Vistin Pharma ASA: Minutes from the annual general meeting 2025
English 897.7 KB
2025-05-22 12:59
Post-Annual General Meeting Information
Vistin Pharma ASA: Minutes from the annual general meeting 2025
English 736 bytes
2025-05-22 09:56
Proxy Solicitation & Information Statement
Disclosure of voting rights at AGM in Vistin Pharma ASA
English 963 bytes
2025-05-07 13:30
Board/Management Information
Vistin Pharma ASA (VISTN): Update from the Election Committee
English 1.3 KB

Automate Your Workflow. Get a real-time feed of all Vistin Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vistin Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vistin Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden
ERMA
Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ

Talk to a Data Expert

Have a question? We'll get back to you promptly.